Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis

BACKGROUND: Pirfenidone was recently approved for treatment of idiopathic pulmonary fibrosis. However, the therapeutic dose of pirfenidone is very high, causing side effects that limit its doses and therapeutic effectiveness. Understanding the molecular mechanisms of action of pirfenidone could impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yan, Jiang, Haihong, Zhang, Qian, Mehrotra, Suneet, Abel, Peter W., Toews, Myron L., Wolff, Dennis W., Rennard, Stephen, Panettieri, Reynold A., Casale, Thomas B., Tu, Yaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994235/
https://www.ncbi.nlm.nih.gov/pubmed/27549302
http://dx.doi.org/10.1186/s12931-016-0418-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994235/
https://www.ncbi.nlm.nih.gov/pubmed/27549302
http://dx.doi.org/10.1186/s12931-016-0418-4

Ejemplares similares